Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
11.01.2022 08:00:25

Edison Investment Research Limited: Agronomics (ANIC) Initiation - At the forefront of a new agrarian revolution

Edison Investment Research Limited
Edison Investment Research Limited: Agronomics (ANIC) Initiation - At the forefront of a new agrarian revolution

11-Jan-2022 / 07:00 GMT/BST


 

London, UK, 11 January 2021

 

Agronomics (ANIC) Initiation - At the forefront of a new agrarian revolution

Agronomics (ANIC) invests in companies producing environmentally friendly alternatives to traditionally produced meat, dairy, seafood, materials and other agricultural products. It aims to create long-term value for shareholders by investing mainly in private, early-stage companies and supporting them to sale, or public listing and commercial viability. ANIC is the only UK-listed vehicle targeting cellular agriculture, offering investors a rare opportunity to gain exposure to this exciting and rapidly expanding sector, which is likely to generate broad-based disruption to conventional agriculture. ANIC's strategy is supported by growing awareness of environmental issues. It has had an early mover advantage, possesses a reputation for expertise in the sector and has a level of access to follow-on and new investments unusual in the sector. Early performance has been promising and the company is trading at a premium to NAV. While it will take time for ANIC's investments to become commercially viable, significant valuation appreciation typically precedes large-scale commercialisation within the sector. And the valuations of more advanced, plant-based protein companies suggest the possibility of substantial long-term upside for patient investors.

ANIC's share price trades at a premium to cum-income NAV (using conservative, IFRS valuation methodology) thanks in part to its increasing popularity with investors and the scarcity of alternative investment options in the cellular agriculture sector. These factors, combined with a 'backward-looking' NAV, suggest the premium is likely to persist for the foreseeable future.


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Joanne Collins +44 (0)20 3077 5700  investmenttrusts@edisongroup.com

Sara Welford +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1266793  11-Jan-2022 

fncls.ssp?fn=show_t_gif&application_id=1266793&application_name=news&site_id=smarthouse

Nachrichten zu Port Erin Biopharma Investments Ltdmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Port Erin Biopharma Investments Ltdmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Port Erin Biopharma Investments Ltd 0,04 -1,18% Port Erin Biopharma Investments Ltd